Better Medicare Alliance Applauds Withdrawal of the Proposed Rebate Rule
THE ADMINISTRATION WITHDRAWS PROPOSED REBATE RULE THAT WOULD HAVE INCREASED BENEFICIARIES PREMIUMS IN MEDICARE ADVANTAGE AND HAD THE POTENTIAL TO REDUCE SUPPLEMENTAL BENEFITS
Washington, D.C. – Better Medicare Alliance (BMA) President and CEO Allyson Y. Schwartz released the following statement in response to the Health and Human Services’ Office of Inspector General’s proposed rule eliminating current safe harbors for Medicare prescription drug rebates:
“BMA applauds the Administration’s withdrawal of the proposed rebate rule in Part D which would have had the harmful effect of increased premiums or reduced benefits for millions of beneficiaries in Medicare Advantage. We share the Administration’s goal of lowering prescription drug out-of-pocket costs for consumers and believe that action to reduce costs should address the root cause of high prescription drug prices. We look forward to working with the Administration and Congress to address high prices while protecting the high-quality, affordable prescription drug coverage provided in Medicare Advantage.
Better Medicare Alliance provided analysis of the impact of the proposed rule, galvanized many of our ally organizations and beneficiaries to explain the harmful effects, including the effect on the 4 million beneficiaries in Employer Group Waiver Plans. On behalf of these allies and beneficiaries, we are pleased the Administration took this step to withdraw the rule.”
Coalition of 15 National Health Care Organizations Say NO to Rebate Rule
Analysis of Rebate Rule on Medicare Advantage